CEO Park Kwan-soo graduated from Chung-Ang University and majored in pharmacology at the same graduate school (master’s). Since then, he has worked for 37 years in the pharmaceutical field including drug development and clinical trials at domestic and overseas pharmaceutical companies such as LG Life Science, Daewoong Pharmaceutical, and Hyundai Pharm. From 2018 to 2020, he served as the chairman of KCROA (Korea Clinical CRO Association).
CEO Park Kwan-soo said, “We will provide high-quality services in response to various requests from drug developers in the fields such as domestic and international clinical trials and approvals through human resource development, strengthening of professional competence, establishment of efficient processes, and active communication.” By establishing an organic cooperation system with domestic and overseas institutions, we will strengthen our trust as a partner of domestic and global drug and medical device developers.”
Meanwhile, Seoul CRO, a subsidiary of Cha Biotech, established in 2009, is a leading clinical trial consignment specialist that performs all the processes necessary for clinical trials, from clinical trial plan, monitoring, clinical data management, statistical processing, and final result report creation. In addition, based on global networks such as Japan and China, including Korea, it provides a one-stop service for all tasks ranging from individual strategy consulting, licensing, and item approval for each country.
Cha Biotech has 10 domestic and 29 overseas subsidiaries including Seoul CRO, CMG Pharmaceuticals, and Cha Vaccine Research Institute, and is connected with Cha Medical Science University, research institutes and hospitals (68 sites in 7 countries) It is building an industry, academia, research, and disease system that combines rapid and effective clinical and global business development capabilities.
Seoul CRO, a subsidiary of Cha Biotech, is expanding its business by using the global network of Cha Bio Group and Cha Hospital to support domestic bio-pharmaceutical companies’ overseas expansion and securing multinational pharmaceutical companies as customers.